InflaRx NV
(NASDAQ : IFRX)

( )
IFRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -11.87%310.610.0%$5071.29m
BNTXBioNTech SE -4.91%334.480.0%$1509.60m
NVAXNovavax, Inc. -7.66%192.6578.2%$1000.81m
AMGNAmgen, Inc. 0.97%200.801.4%$596.73m
GILDGilead Sciences, Inc. 0.00%68.931.0%$502.66m
REGNRegeneron Pharmaceuticals, Inc. -0.93%630.592.7%$480.14m
VRTXVertex Pharmaceuticals, Inc. 9.66%205.001.9%$469.49m
LGVNLongeveron Inc. -22.20%20.430.0%$404.67m
ILMNIllumina, Inc. -2.10%357.663.3%$316.55m
SNSSSunesis Pharmaceuticals, Inc. -10.85%4.110.7%$287.30m
BIIBBiogen, Inc. -2.65%229.501.8%$286.58m
OCGNOcugen, Inc. -4.89%6.030.0%$251.60m
INCYIncyte Corp. -4.08%64.962.4%$161.20m
EXASEXACT Sciences Corp. -5.96%80.2818.0%$157.41m
SGENSeagen Inc. -1.09%158.255.8%$147.19m

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.